CVS Caremark Corp (CVS)
CVS (NYSE:Retail)
$59.44

+0.07
+0.12%
Today's Range: 59.04 - 59.64 |
CVS Avg Daily Volume: 5,826,500
| Last Update: 05/17/13 - 4:02 PM EDT |
| Volume: 4,131,290 |
| YTD Performance: 22.94%
|
| Open: $59.33 |
| Previous Close: $59.37 |
| 52 Week Range: $43.30 -
$60.66 |
| Oustanding Shares: 1,224,392,685 |
| Market Cap: 72,692,193,708 |
6-Month Chart
TheStreet Ratings Grade for CVS
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
11 |
12 |
13 |
14 |
| Moderate Buy |
3 |
3 |
3 |
3 |
| Hold |
1 |
1 |
1 |
1 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.30 |
1.28 |
1.26 |
1.25 |
| Latest Dividend: |
0.23 |
| Latest Dividend Yield: |
1.52% |
| Dividend Ex-Date: |
04/19/13 |
| Price Earnings Ratio: |
18.50 |
|
| Price Earnings Comparisons: |
| CVS |
Sector Avg. |
S&P 500 |
| 18.50 |
18.60 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
16.28%
|
32.47%
|
65.71%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
15.00 |
0.25 |
0.08 |
| Net Income |
12.10 |
0.05 |
0.02 |
| EPS |
17.50 |
0.18 |
0.06 |
| Earnings for CVS: |
| EBITDA |
8.98B |
| Revenue |
123.13B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.96 |
$0.97 |
$3.97 |
$4.40 |
| Number of Analysts |
9 |
8 |
11 |
11 |
| High Estimate |
$0.98 |
$1.00 |
$4.00 |
$4.52 |
| Low Estimate |
$0.93 |
$0.94 |
$3.92 |
$4.20 |
| Prior Year |
$0.81 |
$0.85 |
$3.44 |
$3.97 |
| Growth Rate (Year over Year) |
18.38% |
13.97% |
15.27% |
11.07% |
May 09, 2013 | 8:19 AM EDT
CVS Caremark Corporation Annual Shareholder Meeting - 8:30AM
| Mar 14, 2013 | 11:30 AM EDT
Mar 14, 2013 | 7:39 AM EDT
CVS earnings estimates were increased, said UBS. Health reform and generics will benefit the company in 2014/2015. Price target is now ...
| Feb 25, 2013 | 8:30 AM EST
Stocks that defy correction and those ripe for correction.
Feb 07, 2013 | 8:17 AM EST
CVS estimates were raised through 2014, Guggenheim said. Company boosted its guidance. Buy rating and new $60 price target.
| Feb 06, 2013 | 7:57 AM EST
Short-term traders will likely give the benefit of the doubt to the bulls.
Jan 09, 2013 | 7:13 AM EST
JPMorgan Global Healthcare Conference (Day 4 of 5) - 01/06/13 - 01/10/13 San Francisco, CA
Dec 20, 2012 | 8:06 AM EST
CVS estimates were raised through 2014, Jefferies said. Company can expand margins and repurchase more shares. Buy rating and new $58 p...
Dec 14, 2012 | 8:27 AM EST
CVS estimates were raised through 2014, Lazard said. Company boosted its guidance. Buy rating and new $48.50 price target.
Dec 13, 2012 | 6:57 AM EST
CVS Caremark Corporation Analyst Meeting - 8AM